ABSTRACT
Background: The objective of the present study was to categorize serous effusions in accordance with the Indian Academy of Cytology (IAC) guidelines, evaluate the characteristics of various types of serous effusions using cytological findings, and determine the risk of malignancy within different diagnostic categories. Methods: The study conducted at a tertiary care teaching hospital focused on patients with pleural, and peritoneal effusions/ascitic fluid, using retrospective data from patient records. Samples sent to the pathology department for cytopathological analysis over a one-year period after obtaining approval from institutional ethics committee (IEC). The statistical methods used included descriptive statistics and frequency analysis to examine the different cell types and characteristics present in the effusions. Risk of malignancy was calculated for each category. A Chi-square test was used to assess the relationship between different diagnostic categories, with a p value of <0.05 indicating statistical significance. Results: The findings of the study indicate that out of a total of 161 cases, there were 127 (78.88%) male patients and 34 (21.12%) female patients, resulting in a male to female ratio of 18:5. Ascitic fluid was present in 103 cases (64%) and pleural fluid in 58 cases (36%). The majority of cases, 148 (91.92%), fell into the benign category, followed by 5 cases (3.10%) in category 3, 3 cases (1.86%) in category 5, 2 cases (1.24%) in category 4, and 3 cases (1.86%) in category 1. A statistically significant p value of 0.04 was found among the different diagnostic categories. Conclusions: The IAC has specific guidelines and recommendations for reporting serous effusion cytology to ensure accurate and consistent interpretation of results. In conclusion, reporting serous effusion cytology according to IAC guidelines is essential for accurate diagnosis, prognostic information, quality assurance, communication with the healthcare team, and promoting research and education in the field. Adhering to these guidelines ensures standardized reporting practices and improves patient care outcomes.
ABSTRACT
Background: The present study was planned to compare of pre and post donation hematological parameters in healthy donors by plateletpheresis. Also to assess the platelet yield following plateletpheresis procedure with its correlation to pre donation platelet count. Methods: This is a retrospective cross-sectional study carried out in the Blood Centre of a tertiary care hospital in Haryana, India between January to December 2022. Plateletpheresis was done on Trima Accel Automated Collection System with ACD?A as an anticoagulant. The data was collected from the hospital for hematological parameters (Hb, hematocrit, Total WBC count, total platelet count) pre and post donation. Categorical data is presented as frequency, percentage, mean±SD range. Correlation was established between the pre donation platelet count and the platelet yield. Results: A total of 125 donors were included in the study with majority of the donors 69 (55.2%) in the age group 21-30 years. Mean age of the donors included in the study was 31.58±7.5 years. The levels of hemoglobin dropped from 14.16±0.95 to 13.92±1.002 gm/dl, hematocrit dropped from 41.19±1.33 to 40.91±2.89%, total WBC count reduced from 7.64±1.38 to 7.61±1.36 103/ l and platelet count dropped from 279.5±62.96 to 259.9±58.38 lac/ l. There was a significant drop in the levels of platelet post donation by 7.01% compared to pre donation levels. majority of the donors (44%) had a mean platelet yield 2.49±0.33 with a platelet count between 1.5-2.5x1011/l. The maximum platelet yield was 4.93±0.34 in 6% donors with pre-donation platelet count of >4.5 5x1011/l. A linear significant relationship was established between the platelet count and the platelet yield (r=0.99). Conclusions: There were significant changes in the pre donation and post donation hematological parameters among the donors. It was concluded that donors with a high pre-donation platelet count can be considered for better platelet yield.
ABSTRACT
AIM: The outcome of patients with advanced gastrointestinal stromal tumor (GIST) has improved with the use of imatinib. Despite high response rates with this drug resistance eventually develops in nearly all patients. We present an analysis of prospectively collected data on sunitinib efficacy and safety in patients with imatinib‑resistant GIST. SUBJECTS AND METHODS: Between November 2006 and October 2007, patients with GIST were accrued in an approved sunitinib patient access protocol. Key eligibility criteria included tumor resistance to imatinib and/or patient intolerance to this drug. Patients received sunitinib at a starting dose of 50 mg once daily for 4 weeks in a 6 week cycle, with standardized dose modification titrated to toxicity. Patients were continued on sunitinib until disease progression or unacceptable toxicity. The endpoints were safety, overall survival (OS) and objective response rate (ORR). RESULTS: Fifteen patients, all of whom had imatinib resistance and none intolerance, with median age of 48 (26–69) years, were treated on the protocol. The most common sites of primary disease were small intestine (40%), stomach (26.7%) and retroperitoneal (26.7%). A median of 10 (1–47) cycles of sunitinib were delivered, 9 (60%) patients required dose reductions due to toxicity whereas dose delay of > 2 weeks was required in only one (6.7%) patient. There were no toxicity‑related drug discontinuations. Hypothyroidism (n = 4; 26.7%) and hand‑foot syndrome (n = 3; 20%) were the most common toxicities. There were no complete and 4 (26.7%) partial responses while prolonged disease stability was seen in 8 (53.3%) patients. At a median follow‑up of 81 months in surviving patients, the median progression‑free and overall survivals were 15.5 and 18.7 months, respectively. CONCLUSIONS: Sunitinib appears to be an effective and well‑tolerated treatment for Indian patients with imatinib‑resistant GIST with outcomes similar to that reported previously. Adverse effects can be reasonably well managed using a dose modification strategy.
ABSTRACT
Livestock is an important sector of agriculture in Haryana. It brings cash income to the rural families, bringing protection against the social depressions in addition to providing the food products of high nutritional value. In present study we have discussed ethnoveterinary uses, mode of administration, doses and duration of 54 medicinal plant species belonging to 37 families for treating routine maladies of livestock. About 80% interviewed people gained their knowledge of traditional medicine from their parents and grandparents and others gained from neighbours and co-producers. It has been observed that older persons and traditional healers have greater knowledge about traditional medicines than younger persons. In the present study it was found that many plants viz. Acacia nilotica, Argemone mexicana, Azadirachta indica, Calotropis procera, Citrullus colocynthis, Trachyspermum ammi, Zizyphus nummularia etc. are used for treating more than one disease. It has also been observed that freshly collected plants or plants parts are used in treatment. Though, the findings presented in this paper are preliminary and needs further authentication but these findings can aid the development of indigenous knowledge and its use to the benefits of various fields of study such as pharmacology, pharmacognosy, pharmaceuticals, toxicology, phytochemistry, ethnobotany, taxonomy, anthropology and veterinary science.
ABSTRACT
Impact Factor for 2013 is 1.131 Click here to download free Android Application for this and other journals Click here to view optimized website for mobile devices Journal is indexed with MEDLINE/Index Medicus and Science Citation Index ExpandedShare on facebookShare on twitterShare on citeulikeShare on connoteaShare on googleShare on linkedinMore Sharing Services MINI SYMPOSIUM: HEAD NECK CANCER Year : 2013 | Volume : 50 | Issue : 1 | Page : 1-8 Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference? VM Patil1, V Noronha1, VK Muddu1, S Gulia1, B Bhosale1, S Arya2, S Juvekar2, P Chatturvedi3, DA Chaukar3, P Pai3, A D'cruz3, K Prabhash1 1 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India 2 Department of Radio-Diagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India 3 Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India Date of Web Publication 20-May-2013 Correspondence Address: K Prabhash Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra India DOI: 10.4103/0019-509X.112263 PMID: 23713035 » Abstract Background: Locally advanced and unresectable oral cavity cancers have a poor prognosis. Induction might be beneficial in this setting by reducing tumor bulk and allowing definitive surgery. Aim: To analyze the impact of induction chemotherapy on locally advanced, technically unresectable oral cavity cancers. Materials and Methods: Retrospective analysis of patients with locally advanced oral cavity cancers, who were treated with neoadjuvant chemotherapy (NACT) during the period between June 2009 and December 2010. Data from a prospectively filled database were analyzed for information on patient characteristics, chemotherapy received, toxicity, response rates, local treatment offered, patterns of failure, and overall survival. The statistical analysis was performed with SPSS version 16. Results: 123 patients, with a median age of 42 years were analyzed. Buccal mucosa was the most common subsite (68.30%). Three drug regimen was utilized in 26 patients (21.10%) and the rest received two drug regimen. Resectability was achieved in 17 patients treated with 3 drug regimen (68.00%) and 36 patients receiving 2 drug regimen. Febrile neutropenia was seen in 3 patients (3.09%) receiving 2 drug regimen and in 9 patients (34.62%) receiving 3 drug regimen. The estimated median OS was not reached in patients who had clinical response and underwent surgery as opposed to 8 months in patients treated with non-surgical modality post NACT (P = 0.0001). Conclusion: Induction chemotherapy was effective in converting technically unresectable oral cavity cancers to operable disease in approximately 40% of patients and was associated with significantly improved overall survival in comparison to nonsurgical treatment.